Evidence map›Paper›PMID 36466103›Full record

ArticleEuroasian journal of hepato-gastroenterology2022

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.

Shivaram P Singh, Prajna Anirvan, Amna S Butt, Ananta Shrestha, Anuradha S Dassanayake, Bashir A Shaikh, Mamun A Mahtab

Abstract read
In one paragraph

Article in Euroasian journal of hepato-gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD.Journal of clinical and experimental hepatology
    Review
  2. Article
  3. MASLD, MLA Pesarattu and Other Developments.Journal of clinical and experimental hepatology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shivaram P SinghDepartment of Gastroenterology, SCB Medical College and Hospital, Cuttack, Odisha, India.
Prajna AnirvanDepartment of Gastroenterology, SCB Medical College and Hospital, Cuttack, Odisha, India.
Amna S ButtSection of Gastroenterology, Department of Medicine, The Aga Khan University Hospital, Karachi, Sindh, Pakistan.ORCID https://orcid.org/0000-0002-7311-4055
Ananta ShresthaAlka Hospital, Kathmandu, Nepal.ORCID https://orcid.org/0000-0002-8410-4637
Anuradha S DassanayakeColombo North Centre for Liver Disease, Faculty of Medicine/University of Kelaniya, Colombo, Sri Lanka.ORCID https://orcid.org/0000-0001-5567-3542
Bashir A ShaikhDepartment of Medicine, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Sindh, Pakistan.
Mamun A MahtabDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.ORCID https://orcid.org/0000-0003-3728-3879

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: There have been vociferous attempts to change the name of Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Associated Fatty Liver Disease (MAFLD). Of the many arguments put forth in support of this, an important one is the presumed demand by patient groups insisting on the change. However, this claim does not have credible evidence to support it. Therefore, we decided to conduct a survey among South Asian NAFLD patients to understand their perspectives with regard to the change in nomenclature. Materials and Methods: The study was conducted at multiple centers across South Asia from January 2021 to June 2021. Patients were surveyed using an 8-question survey questionnaire and responses were categorized by multiple-choice format. Results: Of 218 patients surveyed, 80.3% of the patients were not aware of the entity "NAFLD" before they were first diagnosed. Although 74.3% of patients admitted to being questioned about alcohol intake at the time of the first diagnosis, 75.9% of female patients were not questioned regarding this. After being labelled NAFLD, 92.1% of patients were never questioned again about alcohol intake. While 86.3% of patients found the term "NAFLD" consoling, 83% did not feel that "Non" in NAFLD trivialized their problem. In addition, only 6.9% of patients were scared of developing cardiovascular disease. Conclusion: The term "NAFLD" destigmatizes patients of the taboo associated with alcohol use. It was found to be consoling to most patients and they did not feel it trivialized their problem. A change of name without considering patients' perspectives and peculiarities specific to different populations will have enormous ramifications for both patients and physicians. Clinical significance: Our survey clearly shows that patients are happy with the term "NAFLD" and it effectively destigmatizes them from the taboo of alcohol. This would lead to higher compliance with management and greater patient participation in future studies and trials. How to cite this article: Singh SP, Anirvan P, Butt AS,

Indexed as

NASHNomenclaturepatients' sentimentsSouth AsiaSteatohepatitis

Identifiers

PMID36466103
PMCPMC9681577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.